Login to Your Account



MedImmune Expects To Take FluMist Back To Panel This Year

By Kim Coghill


Monday, October 28, 2002
An FDA advisory panel later this year is expected to vote on whether FluMist should enter the market as a nasal influenza vaccine for patients who are ages 19 months to 64 years old. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription